Meeting
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
Authors
Biyun Wang
Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Biyun Wang , Shuhui You , Yizhao Xie , Mengjing Ji , Zhongyi Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1034)
DOI
10.1200/JCO.2023.41.16_suppl.1034
Abstract #
1034
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer.
First Author: Beth Overmoyer
Poster
2024 ASCO Annual Meeting
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
First Author: Nicholas Mai
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis.
First Author: Chiara Molinelli